Tag: Neurocritical care

Following an aneurysmal subarachnoid hemorrhage (aSAH), patients are at significant risk of delayed cerebral ischemia (DCI), a leading cause of severe disability and mortality. The standard of care to mitigate this risk involves a specific CCB: Nimodipine.

Hemorrhagic strokes account for about 10-15% of all strokes and have a higher mortality rate than other types [1.7.1, 1.7.3]. The pressing question for clinicians is, what medication is used for hemorrhagic stroke to give patients the best chance of survival and recovery?

Subarachnoid hemorrhage (SAH) is a devastating type of stroke, with approximately 55% of patients being under the age of 55 when the event occurs. The primary pharmacological intervention used to manage this condition is nimodipine, answering the critical question: what is the drug of choice for subarachnoid hemorrhage? This calcium channel blocker is a cornerstone of treatment, aiming to improve neurological outcomes and prevent complications.

With a global market value of approximately $1.62 billion in 2022, the **what is the market for aneurysmal subarachnoid hemorrhage drugs?** is driven by the high mortality rates and severe complications associated with this life-threatening form of stroke. This market is marked by ongoing innovation and a focus on improving patient outcomes through both standard and emerging pharmacological interventions.

In 2021, there were over 69,000 traumatic brain injury (TBI)-related deaths in the United States, highlighting the critical need for precise medical management [1.7.2]. A key question in treatment is: **can lorazepam be given in head injury?** The answer is complex, involving specific applications and significant risks.

For up to 90% of patients with aneurysmal subarachnoid hemorrhage (aSAH), severe headache is a major and often persistent symptom during hospitalization. Given the complex and delicate nature of a brain bleed, selecting the appropriate **medication used for brain bleed headaches** requires careful consideration to manage pain effectively without causing further complications. This article provides a comprehensive overview of pharmacological strategies used in neurocritical care for treating headaches associated with intracranial hemorrhage.

Increased intracranial pressure (ICP) is a critical medical emergency that can lead to severe brain damage or death if not promptly treated. A key part of treatment involves identifying which medication is commonly used to manage increased intracranial pressure and administering it to reduce swelling.

Intracranial hypertension, a sustained pressure above 20 mmHg, is a life-threatening emergency often seen after traumatic brain injury, and its presence significantly increases the risk of death [1.2.2]. So, in these critical moments, **what does hypertonic saline do to the brain?**

Brain swelling, a potentially life-threatening condition, occurs in response to many injuries, tumors, and infections. Understanding **what medication is used to reduce brain swelling** is critical for managing increased intracranial pressure and preventing severe neurological damage.